vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman purchased 1,879,700 shares of the company’s stock in a transaction dated Thursday, November 29th. The shares were acquired at an average price of $1.33 per share, for a total transaction of $2,500,001.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Shares of VTVT stock traded up $0.04 during trading hours on Friday, reaching $1.69. 213,800 shares of the company’s stock were exchanged, compared to its average volume of 1,421,310. vTv Therapeutics Inc has a 1 year low of $0.65 and a 1 year high of $8.40. The firm has a market capitalization of $64.79 million, a price-to-earnings ratio of -1.01 and a beta of -3.71.
vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.06. The business had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $2.06 million. As a group, equities analysts expect that vTv Therapeutics Inc will post -0.73 earnings per share for the current year.
An institutional investor recently raised its position in vTv Therapeutics stock. Millennium Management LLC boosted its position in vTv Therapeutics Inc (NASDAQ:VTVT) by 51.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 95,031 shares of the biotechnology company’s stock after buying an additional 32,362 shares during the period. Millennium Management LLC owned approximately 0.29% of vTv Therapeutics worth $387,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 2.17% of the company’s stock.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.